LYEL News and Press, Lyell Immunopharma Inc. From 07/25/25

SOUTH SAN FRANCISCO, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, today announced that it has entered into a securities purchase agreement for a private placemen...

2025-07-22 09:02:07 ET Lyell Immunopharma ( LYEL ) has made significant progress with respect to its CD19/CD20 CAR-T cell therapy targeting patients with aggressive 3rd-line + Large B-Cell Lymphoma [LBCL]. The reason why is because it had been reported that these specific patien...

2025-07-18 16:42:21 ET More on Lyell Immunopharma Lyell Immunopharma strengthens clinical and commercial capabilities with executive appointments Seeking Alpha’s Quant Rating on Lyell Immunopharma Historical earnings data for Lyell Immunopharma Financi...

SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will participate in the H.C. Wainwri...

LYL314 demonstrated robust clinical responses, with an 88% overall response rate and a 72% complete response rate in patients treated in the third- or later-line setting (N = 25) 71% of patients with complete response remained in complete response at ≥ 6 months Manageable safety pr...

2025-06-10 01:52:53 ET More on Lyell Immunopharma Lyell Immunopharma gets FDA RMAT status for lymphoma treatment Seeking Alpha’s Quant Rating on Lyell Immunopharma Historical earnings data for Lyell Immunopharma Financial information for Lyell Immunoph...

Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of Directors David Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN ...

Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18 th International Conference on Malignant Lym...

Redwire Corporation (RDW) is expected to report $-0.2 for Q1 2025 Organigram Global Inc. (OGI) is expected to report $-0.03 for Q2 2025 Inter & Co. Inc. (INTR) is expected to report $0.12 for Q1 2025 Pervasip Corp (PVSP) is expected to report for quarter end 2025-02-28 Maui La...

National Health Investors Inc. (NHI) is expected to report $1.13 for Q1 2025 Palomar Holdings Inc. (PLMR) is expected to report $1.45 for Q1 2025 Weave Communications Inc. (WEAV) is expected to report $-0.11 for Q1 2025 First National Bank Alaska (FBAK) is expected to report for Q1 20...